Glioblastoma Multiforme: Global Drug Forecast and Market Analysis to 2030

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Glioblastoma multiforme (GBM) is now defined by the WHO 2021 as a diffuse astrocytic glioma with no mutations in IDH genes or histone H3 genes. It is the most common primary brain tumor in humans. Like other astrocytomas, GBM originates from astrocytes, a type of glial cells that are non-neuronal and function to provide structural and biochemical support to the brain’s neuronal network. GBM continues to be a disease with some of the highest unmet needs in oncology, with patients having a median overall survival (OS) of between one and two years. The lack of therapies is primarily due to the inability of drugs to penetrate the blood-brain barrier (BBB).
The market of GBM relies predominantly on temozolomide and bevacizumab, which accounted for 46% and 51%, respectively, of the total $549.1M sales in 2020. For this market to witness true growth, the currently marketed products would need to be almost entirely replaced by new pipeline products, owing to the significant presence of generic temozolomide and the introduction of bevacizumab biosimilars. However, a high failure rate has been historically observed for late-stage GBM trials and may impact the pipeline forecast and impede the market growth. Nevertheless, eight pipeline agents are expected to enter the 8MM and drive the GBM growth to $868.5M by 2030 at a Compound Annual Growth Rate (CAGR) of 4.7%.

Eight Phase II-III pipeline agents are expected to enter the Glioblastoma market from 2024 onwards. What impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
What are the current unmet needs in GBM, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
What are the current research and development (R&D) strategies being explored and how can developers incorporate these methods into their business strategy?
What is the expected future uptake of protein kinase inhibitors across the 8MM?


Overview of Glioblastoma Multiforme including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Topline Glioblastoma Multiforme market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.

Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting Glioblastoma Multiforme therapeutics sales in the 8MM.

Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase II – III).

Analysis of the current and future market competition in the global Glioblastoma Multiforme therapeutics market. Insightful review of the key industry drivers and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

The main drivers of growth include the anticipated approval and launch of eight pipeline agents during the forecast period, of which cancer vaccines and protein kinase inhibitors are the dominating classes.

The primary barrier to growth in the forecast period will be the high failure rates historically observed for Phase III GBM trials, impacting the pipeline forecast. The high genericization of temozolomide and recent patent expiration of Avastin, leading to biosimilar entry, also reduces the Glioblastoma Multiforme (GBM) market potential.

DCVax-L, regorafenib, and paxalisib are the three pipeline agents expected to generate the highest sales for GBM from 2020-2030.

Aside from improving OS, other key unmet needs in the GBM market include; Predictive biomarkers to guide personalized therapy and the need to find more efficacious treatment in O6-methylguanine-DNA methyltransferase (MGMT) unmethylated patients who typically have a poor response to temozolomide.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.

Develop business strategies by understanding the trends shaping and driving the global Glioblastoma Multiforme therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Glioblastoma Multiforme market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track drug sales in the global Glioblastoma Multiforme therapeutics market from 2020-2030.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Merck & Co
NextSource Biotechnology
Heritage Pharmaceuticals (Emcure)
Daiichi Sankyo
Nipro ES Pharma
Kazia Therapeutics
Kintara Therapeutics
Epitopoietic Research Corporation
Denovo Biopharma
CNS Pharmaceuticals
Northwest Biotherapeutics
Laminar Pharmaceuticals

Table of Contents

| Contents

| List of Tables

| List of Figures

| About GlobalData

1 Glioblastoma Multiforme: Executive Summary

1.1 The Glioblastoma Multiforme Market is Forecast to Reach $868.5M by 2030 Across the 8MM

1.2 GBM-AGILE Candidates Set to Penetrate the Market While Merck & Co. Expands its Early-Stage Portfolio and Roche Experiences Erosion

1.3 High Unmet Needs Exist in the GBM Market, Especially in MGMT-Promoter Unmethylated Patients and Unresectable Patients

1.4 Opportunities for New Entrants with Better Markers of Prognosis and Drug Targets

1.5 Novel GBM-AGILE Drug Candidates and Immunotherapies Expected to Launch During the Forecast Period

1.6 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification or Staging Systems

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.4 8MM Forecast Methodology

4.4.1 Sources

4.4.2 Forecast Assumptions and Methods

4.4.3 Diagnosed Incident Cases of Brain Cancer

4.4.4 Diagnosed Incident Cases of Brain Cancer by Type

4.4.5 Diagnosed Incident Cases of Glioblastoma by Grade

4.4.6 Diagnosed Incident Cases of Glioblastoma by Origin

4.4.7 Diagnosed Incident Cases of Glioblastoma by Biomarkers

4.4.8 Diagnosed Incident Cases of Glioblastoma by Mutations

4.4.9 Five-Year Diagnosed Prevalent Cases of Brain Cancer

4.5 Discussion

4.5.1 Epidemiological Forecast Insight

4.5.2 COVID-19 Impact

4.6 Epidemiological Forecast for Brain Cancer (2020–2030)

4.6.1 Diagnosed Incident Cases of Brain Cancer

4.6.2 Age-Specific Diagnosed Incident Cases of Brain Cancer

4.6.3 Sex-Specific Diagnosed Incident Cases of Brain Cancer

4.6.4 Diagnosed Incident Cases of Brain Cancer by Type

4.6.5 Diagnosed Incident Cases of Glioblastoma by Grade

4.6.6 Diagnosed Incident Cases of Glioblastoma by Origin

4.6.7 Diagnosed Incident Cases of Glioblastoma by Biomarkers

4.6.8 Diagnosed Incident Cases of Glioblastoma by Mutations

4.6.9 Five-Year Diagnosed Prevalent Cases of Brain Cancer

4.6.10 Limitations of the Analysis

4.6.11 Strengths of the Analysis

5 Disease Management

5.1 Diagnosis and Treatment Overview

5.2 KOL Insights on Disease Management

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Identification and Validation of Biomarkers and Drug Targets

7.3 Overcoming the Blood-Brain Barrier to Improve the Efficacy of Treatments

7.4 Better Treatment Options for MGMT Unmethylated and Unresectable Patients

7.5 Differentiating Pseudoprogression and True Progression

9 R&D Strategies

9.1 Overview

9.1.1 The Efficacy of Immunotherapy in GBM

9.1.2 Predictive Biomarkers and Targeted Therapy

9.1.3 Improving Therapy Administration Routes

9.2 Clinical Trials Design

9.2.1 Clinical Endpoints

9.2.2 More Umbrella or Platform Trial Designs

9.2.3 Comparator Arms

10 Pipeline Assessment

10.1 Overview

10.2 Promising Drugs in Clinical Development

11 Pipeline Valuation Analysis

11.1 Overview

11.2 Competitive Assessment

12 Current and Future Players

12.1 Overview

12.2 Deal-Making Trends

13 Market Outlook

13.1 Global Markets

13.1.1 Forecast

13.1.2 Drivers and Barriers – Global Issues

13.2 US

13.2.1 Forecast

13.2.2 Key Events

13.2.3 Drivers and Barriers

13.3 5EU

13.3.1 Forecast

13.3.2 Key Events

13.3.3 Drivers and Barriers

13.4 Japan

13.4.1 Forecast

13.4.2 Key Events

13.4.3 Drivers and Barriers

13.5 China

13.5.1 Forecast

13.5.2 Key Events

13.5.3 Drivers and Barriers

14 Appendix

14.1 Bibliography

14.2 Abbreviations

14.3 Methodology

14.3.1 Forecasting Methodology

14.4 Primary Research – KOLs Interviewed for This Report

14.4.1 KOLs

14.5 Primary Research – Prescriber Survey

14.6 About the Authors

14.6.1 Analyst

14.6.2 Therapy Area Director

14.6.3 Epidemiologist

14.6.4 Managing Epidemiologist

14.6.5 Global Director of Therapy Analysis and Epidemiology

14.6.6 Global Head and EVP of Healthcare Operations and Strategy

14.1 Contact Us

Frequently asked questions

Glioblastoma Multiforme: Global Drug Forecast and Market Analysis to 2030 thematic reports
Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Glioblastoma Multiforme: Global Drug Forecast and Market Analysis to 2030 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Synthetic Biology - Thematic Intelligence
$995 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Glioblastoma Multiforme: Global Drug Forecast and Market Analysis to 2030 in real time.

  • Access a live Glioblastoma Multiforme: Global Drug Forecast and Market Analysis to 2030 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.